REVA Medical to Hold Briefing Call on Financial Results for 2012 and Presentation at Cowen Health Care Conference

REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") will hold a conference call to discuss the Company's financial results through December 31, 2012 and its business outlook. Robert Stockman, Chairman and CEO, will host the call.

The call is scheduled for 2:00 p.m. US PST on Tuesday, March 5, 2013 (which is 9:00 a.m. AEDT on Wednesday, 6 March 2013) and may be accessed within the United States by dialing 1-877-312-5413 five minutes prior to the call. Callers in Australia may access the call by dialing [phone]. If you are asked to provide an access code, please spell out the word "REVA" to the operator and you will be connected promptly. A replay of the audiocast will be available on the Company's website at www.revamedical.com following the call.

Mr. Stockman is also scheduled to present at the Cowen and Company 33rd Annual Health Care Conference at 11:20 a.m. US EST on Wednesday, March 6, 2013. The conference is being held March 4th through 6th at the Boston Marriott Copley Place, in Boston, Massachusetts. A copy of the presentation materials will be available on REVA's website at www.revamedical.com shortly before the presentation.

About REVA

REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialization of its proprietary bioresorbable stent products. The ReZolve® product family, which is in a clinical study phase, combines REVA's proprietary stent design with a proprietary polymer that is metabolized and cleared from the body. REVA's anticipated commercial product, the ReZolve2 scaffold, is designed to offer full x-ray visibility, clinically relevant sizing, and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of scaffold structure over time, the ReZolve2 scaffold may reduce the incidence of late forming blood clots or otherwise reduce long-term disease progression, potential benefits of bioresorbable scaffolds that have yet to be proven. REVA will require clinical results and regulatory approval before it can begin selling the ReZolve2 scaffold.

The REVA Medical, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8505

CONTACT: United States

         Investor and Media Enquiries:
         Cheryl Liberatore
         Director, Investor Relations and Marketing
         REVA Medical, Inc.
         [phone]
         
         Australia

         Investor Enquiries:
         Kim Jacobs or Alan Taylor
         Inteq Limited
         [phone]
         
         Media Enquiries:
         Haley Price or Rebecca Wilson
         Buchan Consulting
         [phone]